Profile data is unavailable for this security.
About the company
Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. The Company’s lead product candidate, XDEMVY is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. The Company investigating the development of its product candidates to address targeted diseases with high unmet medical needs, which include TP-03 for the potential treatment of Meibomian Gland Disease (MGD), TP-04, a novel gel formulation of lotilaner for the potential treatment of rosacea, and TP-05, a novel investigative oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction.
- Revenue in USD (TTM)42.56m
- Net income in USD-148.21m
- Incorporated2016
- Employees244.00
- LocationTarsus Pharmaceuticals Inc15440 Laguna Canyon RoadIRVINE 92618United StatesUSA
- Phone+1 (949) 409-9820
- Fax+1 (302) 531-3150
- Websitehttps://www.tarsusrx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day One Biopharmaceuticals Inc | 0.00 | -208.94m | 1.20bn | 174.00 | -- | 4.05 | -- | -- | -2.50 | -2.50 | 0.00 | 3.40 | 0.00 | -- | -- | 0.00 | -64.27 | -- | -69.93 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.87 | -- | -- | -- |
| BioCryst Pharmaceuticals Inc | 355.40m | -208.59m | 1.27bn | 536.00 | -- | -- | -- | 3.56 | -1.07 | -1.07 | 1.81 | -2.31 | 0.727 | 0.1787 | 6.51 | 663,050.40 | -42.67 | -47.95 | -54.00 | -64.89 | 98.56 | 97.06 | -58.69 | -114.94 | 3.48 | -1.00 | 2.30 | -- | 22.37 | 74.21 | 8.33 | -- | 42.73 | -- |
| Akero Therapeutics Inc | 0.00 | -179.27m | 1.27bn | 58.00 | -- | 1.50 | -- | -- | -3.20 | -3.20 | 0.00 | 12.24 | 0.00 | -- | -- | 0.00 | -28.43 | -37.73 | -29.53 | -40.13 | -- | -- | -- | -- | -- | -- | 0.0395 | -- | -- | -- | -35.46 | -- | -- | -- |
| ANI Pharmaceuticals Inc | 517.46m | 30.57m | 1.29bn | 642.00 | 38.46 | 2.85 | 13.72 | 2.48 | 1.59 | 1.59 | 27.12 | 22.71 | 0.6161 | 1.77 | 2.98 | 806,012.40 | 4.23 | -2.83 | 5.02 | -3.35 | 62.71 | 60.18 | 6.87 | -6.15 | 3.12 | 3.67 | 0.3745 | -- | 53.87 | 19.28 | 131.25 | 0.1754 | 9.08 | -- |
| 4D Molecular Therapeutics Inc | 20.45m | -104.56m | 1.30bn | 171.00 | -- | 2.14 | -- | 63.58 | -2.36 | -2.36 | 0.4841 | 11.74 | 0.0468 | -- | -- | 139,136.00 | -23.93 | -32.67 | -24.71 | -34.90 | -- | -- | -511.20 | -617.15 | -- | -- | 0.00 | -- | 562.29 | 7.96 | 6.19 | -- | 46.26 | -- |
| MannKind Corp | 224.60m | 8.49m | 1.30bn | 414.00 | 204.01 | -- | 96.78 | 5.80 | 0.0234 | 0.0234 | 0.7589 | -0.8492 | 0.5766 | 2.69 | 11.34 | 542,509.70 | 2.18 | -26.07 | 2.84 | -37.80 | 70.99 | 59.68 | 3.78 | -57.61 | 3.57 | 1.50 | 1.80 | -- | 99.42 | 48.17 | 86.34 | -- | 160.47 | -- |
| Tarsus Pharmaceuticals Inc | 42.56m | -148.21m | 1.32bn | 244.00 | -- | 4.80 | -- | 31.08 | -4.72 | -4.72 | 1.35 | 7.29 | 0.1519 | -- | 2.63 | 174,430.30 | -52.88 | -31.56 | -58.73 | -33.82 | 92.37 | -- | -348.22 | -242.59 | 7.92 | -- | 0.0981 | -- | -32.42 | -- | -118.86 | -- | 279.39 | -- |
| Spyre Therapeutics Inc | 688.00k | -364.23m | 1.33bn | 30.00 | -- | -- | -- | 1,931.03 | -71.35 | -71.35 | 0.0456 | 11.08 | 0.0026 | -- | -- | 22,933.33 | -134.88 | -101.87 | -150.32 | -118.83 | -- | -- | -52,939.68 | -2,949.59 | -- | -- | 0.00 | -- | -61.96 | -25.61 | -304.21 | -- | -- | -- |
| Kiniksa Pharmaceuticals Ltd | 301.77m | 8.65m | 1.35bn | 297.00 | 223.59 | 3.12 | 124.43 | 4.48 | 0.0852 | 0.0852 | 4.16 | 6.10 | 0.627 | 1.46 | 25.77 | 1,016,067.00 | 1.80 | -16.49 | 2.01 | -18.72 | 87.75 | -- | 2.87 | -53.64 | 3.79 | -- | 0.00 | -- | 22.74 | -- | -92.32 | -- | -52.35 | -- |
| Pacira Biosciences Inc | 681.75m | 70.47m | 1.38bn | 711.00 | 22.91 | 1.55 | 9.54 | 2.03 | 1.30 | 1.30 | 12.11 | 19.18 | 0.4389 | 1.93 | 7.00 | 958,866.40 | 4.54 | 3.35 | 4.84 | 3.98 | 73.15 | 72.63 | 10.34 | 8.57 | 4.78 | 51.11 | 0.3684 | 0.00 | 1.22 | 14.88 | 163.72 | -- | 0.8761 | -- |
| Belite Bio Inc (ADR) | 0.00 | -32.61m | 1.39bn | 20.00 | -- | 14.07 | -- | -- | -1.18 | -1.18 | 0.00 | 3.24 | 0.00 | -- | -- | 0.00 | -46.26 | -- | -46.26 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -150.09 | -- | -- | -- |
| Cullinan Therapeutics Inc | 0.00 | -132.35m | 1.39bn | 85.00 | -- | 2.44 | -- | -- | -3.14 | -3.14 | 0.00 | 9.88 | 0.00 | -- | -- | 0.00 | -27.85 | -12.37 | -29.31 | -12.93 | -- | -- | -- | -1,026.78 | -- | -- | 0.00 | -- | -- | -- | -237.72 | -- | -4.44 | -- |
| Soleno Therapeutics Inc | 0.00 | -52.03m | 1.43bn | 33.00 | -- | 9.57 | -- | -- | -2.68 | -2.68 | 0.00 | 4.30 | 0.00 | -- | -- | 0.00 | -55.24 | -53.90 | -62.26 | -61.85 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -62.00 | -- | -- | -- |
| Vir Biotechnology Inc | 79.60m | -539.44m | 1.44bn | 587.00 | -- | 0.9262 | -- | 18.03 | -4.01 | -4.01 | 0.5916 | 11.39 | 0.0357 | -- | -- | 135,603.10 | -24.19 | -0.6081 | -27.80 | -0.7192 | 98.85 | -- | -677.69 | -1.53 | -- | -- | 0.00 | -- | -94.67 | 51.87 | -219.24 | -- | 16.77 | -- |
| Xencor Inc | 162.18m | -133.36m | 1.46bn | 280.00 | -- | 2.37 | -- | 8.97 | -2.19 | -2.19 | 2.68 | 9.94 | 0.1922 | -- | 11.02 | 579,217.90 | -15.90 | -3.70 | -17.39 | -4.12 | -- | -- | -82.74 | -15.92 | -- | -- | 0.0323 | -- | 2.28 | 32.90 | -128.50 | -- | 18.36 | -- |
Data as of May 24 2024. Currency figures normalised to Tarsus Pharmaceuticals Inc's reporting currency: US Dollar USD
57.31%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RTW Investments LPas of 31 Mar 2024 | 3.27m | 8.67% |
| Paradigm BioCapital Advisors LPas of 31 Mar 2024 | 2.86m | 7.59% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 2.33m | 6.17% |
| Tang Capital Management LLCas of 31 Mar 2024 | 2.25m | 5.97% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 2.24m | 5.93% |
| Cormorant Asset Management LPas of 31 Mar 2024 | 2.14m | 5.67% |
| Cowen & Co. LLCas of 31 Mar 2024 | 2.12m | 5.62% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.78m | 4.73% |
| Jennison Associates LLCas of 31 Mar 2024 | 1.33m | 3.53% |
| Perceptive Advisors LLCas of 31 Mar 2024 | 1.30m | 3.43% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
